Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of VLX-1005 in Healthy Subjects

NCT04783545
View directory record Official record
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
VLX-1005, Placebo
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
19 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

NCT03983161
View directory record Official record
Conditions
Healthy Volunteers, Hepatic Impairment
Interventions
Fedratinib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

NCT01858935
View directory record Official record
Conditions
Healthy
Interventions
ND-L02-s0201 Injection, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

NCT06529796
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Interventions
IXP
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami, Florida • St. Petersburg, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

NCT06268860
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab vial injection, Rocatinlimab prefilled syringe
Drug · Combination Product
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

NCT03844191
View directory record Official record
Conditions
Coronary Disease
Interventions
RUC-4 Compound
Drug
Lead sponsor
CeleCor Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

NCT01702649
View directory record Official record
Conditions
Healthy Volunteers, Bacterial Infections
Interventions
RPX2003 (Biapenem), Placebo
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-105 in Healthy Adults

NCT04964258
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-105-a, TAK-105-a Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Tempe, Arizona • Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

NCT02155543
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AGN-223575 Formulation A, AGN-223575 Formulation B, AGN-223575 Formulation C, AGN-223575 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

NCT03719443
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
Interventions
VIS649, Placebo
Biological
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study for Safety of ACHN-490

NCT00822978
View directory record Official record
Conditions
Healthy
Interventions
ACHN-490 Injection vs placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

NCT01154621
View directory record Official record
Conditions
Tolerability, Healthy, Elderly
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of N6022 in Healthy Subjects

NCT01147406
View directory record Official record
Conditions
Healthy
Interventions
N6022, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

NCT00989404
View directory record Official record
Conditions
Influenza A Virus, H1N1 Subtype
Interventions
Zanamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

NCT01813448
View directory record Official record
Conditions
Pharmacokinetics of Fidaxomicin, Healthy Subjects
Interventions
Fidaxomicin, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 15, 2026, 8:22 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Single and Multiple Dose of HL-400

NCT06997484
View directory record Official record
Conditions
Parkinson Disease
Interventions
HL-400, Placebo
Drug
Lead sponsor
Highlightll Pharmaceutical (USA) LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

NCT03146416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

NCT05169671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ATH-1020, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

NCT02673567
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TEV-48125 - 1, TEV-48125 - 2, TEV-48125 - 3, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

NCT02342067
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Pioglitazone
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

NCT01413932
View directory record Official record
Conditions
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions
HT-2157, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

NCT01711723
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 15, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

NCT05845996
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SAR441344, placebo, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 15, 2026, 8:22 AM EDT